Chem. J. Chinese Universities ›› 2017, Vol. 38 ›› Issue (7): 1185.doi: 10.7503/cjcu20170064

• Organic Chemistry • Previous Articles     Next Articles

Design of Common Bean Lectin Inhibitor and Its Hemagglutination Activity

LIU Qin1, YU Yanhua2, CHEN Weida1, CHEN Chanyou1, ZHAO Yunjie3,4,*(), ZENG Chen1,4,*()   

  1. 1. School of Life Science
    2. Institute for Interdisciplinary Research, Jianghan University, Wuhan 430056, China
    3. Department of Physics, Central China Normal University, Wuhan 430079, China
    4. Department of Physics, the George Washington University, Washington D.C 20052, USA
  • Received:2017-01-26 Online:2017-07-10 Published:2017-05-23
  • Contact: ZHAO Yunjie,ZENG Chen E-mail:yjzhao.wh@gmail.com;chenz@gwu.edu
  • Supported by:
    † Supported by the Huang He Talent Plan of Wuhan, China(No Wu[2014]3), the Scientific Research Foundation of Central Normal University, China(No.23020205170045) and the Hubei Science and Technology Platform Project, China(No [2011]101)

Abstract:

Common bean(Phaseolus vulgaris L.), rich in protein and low in fat, is one of the most important legume crops in the world. However, consumption of improperly prepared common bean can lead to food poisoning. Previous studies have largely attributed this toxic effect to the high content in lectin, a plant protein that binds specifically to carbohydrate or carbohydrate structures displayed on cell surface. Since most lectin forms a dimer complex for biological functions, a short peptide was designed to break the dimer interface. Detailed dynamical network and structural characteristic analysis were performed to select this peptide. In vitro hemagglutination assay showed that this peptide, upon binding to lectin, disrupts the dimer formation partially and weakens the hemagglutination effect. Taken together, a novel peptide inhibitor was designed whose potency and specificity can be further optimized for anti-hemagglutination and food safety applications.

Key words: Common bean lectin, Molecular dynamics simulation, Drug design, Inhibitor design, Hemagglutination activity

CLC Number: 

TrendMD: